Standard
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. / Stellbrink, Hans-Jürgen; Orkin, Chloe; Arribas, Jose Ramon; Compston, Juliet; Gerstoft, Jan; Van Wijngaerden, Eric; Lazzarin, Adriano; Rizzardini, Giuliano; Sprenger, Herman G; Lambert, John D. C.; Sture, Gunta; Leather, David; Hughes, Sara; Zucchi, Patrizia; Pearce, Helen; ASSERT Study Group.
In:
Clinical Infectious Diseases, Vol. 51, No. 8, 15.10.2010, p. 963-72.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Stellbrink, H-J, Orkin, C, Arribas, JR, Compston, J
, Gerstoft, J, Van Wijngaerden, E, Lazzarin, A, Rizzardini, G, Sprenger, HG, Lambert, JDC, Sture, G, Leather, D, Hughes, S, Zucchi, P, Pearce, H & ASSERT Study Group 2010, '
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study',
Clinical Infectious Diseases, vol. 51, no. 8, pp. 963-72.
https://doi.org/10.1086/656417APA
Stellbrink, H-J., Orkin, C., Arribas, J. R., Compston, J.
, Gerstoft, J., Van Wijngaerden, E., Lazzarin, A., Rizzardini, G., Sprenger, H. G., Lambert, J. D. C., Sture, G., Leather, D., Hughes, S., Zucchi, P., Pearce, H., & ASSERT Study Group (2010).
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Clinical Infectious Diseases,
51(8), 963-72.
https://doi.org/10.1086/656417Vancouver
Stellbrink H-J, Orkin C, Arribas JR, Compston J
, Gerstoft J, Van Wijngaerden E et al.
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Clinical Infectious Diseases. 2010 Oct 15;51(8):963-72.
https://doi.org/10.1086/656417Author
Stellbrink, Hans-Jürgen ; Orkin, Chloe ; Arribas, Jose Ramon ; Compston, Juliet ; Gerstoft, Jan ; Van Wijngaerden, Eric ; Lazzarin, Adriano ; Rizzardini, Giuliano ; Sprenger, Herman G ; Lambert, John D. C. ; Sture, Gunta ; Leather, David ; Hughes, Sara ; Zucchi, Patrizia ; Pearce, Helen ; ASSERT Study Group. / Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. In: Clinical Infectious Diseases. 2010 ; Vol. 51, No. 8. pp. 963-72.
Bibtex
@article{c0669d9b1bf44fc3b9f2f02de10de865,
title = "Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study",
abstract = "Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.",
author = "Hans-J{\"u}rgen Stellbrink and Chloe Orkin and Arribas, {Jose Ramon} and Juliet Compston and Jan Gerstoft and {Van Wijngaerden}, Eric and Adriano Lazzarin and Giuliano Rizzardini and Sprenger, {Herman G} and Lambert, {John D. C.} and Gunta Sture and David Leather and Sara Hughes and Patrizia Zucchi and Helen Pearce and Jan Gerstoft",
year = "2010",
month = oct,
day = "15",
doi = "http://dx.doi.org/10.1086/656417",
language = "English",
volume = "51",
pages = "963--72",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "8",
}
RIS
TY - JOUR
T1 - Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study
AU - Stellbrink, Hans-Jürgen
AU - Orkin, Chloe
AU - Arribas, Jose Ramon
AU - Compston, Juliet
AU - Gerstoft, Jan
AU - Van Wijngaerden, Eric
AU - Lazzarin, Adriano
AU - Rizzardini, Giuliano
AU - Sprenger, Herman G
AU - Lambert, John D. C.
AU - Sture, Gunta
AU - Leather, David
AU - Hughes, Sara
AU - Zucchi, Patrizia
AU - Pearce, Helen
AU - ASSERT Study Group
PY - 2010/10/15
Y1 - 2010/10/15
N2 - Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.
AB - Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.
U2 - http://dx.doi.org/10.1086/656417
DO - http://dx.doi.org/10.1086/656417
M3 - Journal article
VL - 51
SP - 963
EP - 972
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 8
ER -
